Global Meningococcal Disease Treatment Market: Overview
Meningococcal disease is a rigorous infection of meninges; in this disease, the membrane of the brain is affected which causes the brain damage. It is caused by Neisseria meningitides bacteria. This bacterium also causes bloodstream infections. The infection caused by the Neisseria meningitides results in deafness, mental retardation, and epilepsy.
Global Meningococcal Disease Treatment Market: Segmentation
The market for meningococcal disease treatment is globally fragmented into therapy type, route of administration, distribution channel, and regions. On the basis of the therapy type, the global market is segregated into vaccines and antibiotics. The antibiotics segment is sub-segmented into ampicillin, ceftriaxone, penicillin, and chloramphenicol. The vaccines segment is sub-categorized into trivalent, bivalent, and tetravalent. On the basis of the route of administration, the market is categorized into oral and injectable. On the basis of distribution channel, the market is divided into hospital pharmacies, mass vaccination programmes, retail pharmacies, and clinics. Based on the geographical regions, the market is diversified into the Middle East & Africa, North America, Eastern Europe, Western Europe, Latin America, and Asia Pacific.
Global Meningococcal Disease Treatment Market: Growth Factors
In the developing countries which mainly include the Asian and the African countries, there has been an increase in the cases of meningococcal diseases which is the main factor that is driving the global meningococcal disease treatment market. The NGOs and the government organizations have supported the growth of the market by giving financial funding, exporting the medicines and vaccines, and carrying out mass vaccination programs for the prevention of the disease. The developed countries are also making contributions by providing innovative products in the market. Poverty, lack of awareness, illiteracy, and insufficient efforts taken by the governments in order to make healthcare services reformation are hindering the market growth.
Global Meningococcal Disease Treatment Market: Regional Analysis
The largest market for the meningococcal disease treatment is held by Asia and African countries. The main reason for this dominance is the large population base which requires the prevention from the disease and proper treatment for the population that is suffering from the disease. According to the research conducted by the World Health Organization (WHO), the regions that are more prone to this disease involves sub-Saharan African region, to be specific the countries that lie in between Senegal in the west and Ethiopia in the east which involves 26 countries. These regions are known as the extended meningitis belt. In the North America and Europe, the market has a sluggish growth due to the low cases of infection owing to better environmental conditions, advanced healthcare services, and government initiatives for the eradication of this devastating disease.
Global Meningococcal Disease Treatment Market: Competitive Players
The key market players that are involved in the meningococcal disease treatment market include GlaxoSmithKline Plc., Novartis AG, Sandoz International GmbH., F. Hoffmann-La Roche Ltd., Athlone Laboratories, Pfizer Inc., Sanofi Pasteur Inc., Wockhardt, Kent Pharmaceuticals, and Stravencon Limited.
Global Meningococcal Disease Treatment Market: Regional Segment Analysis
What Reports Provides